Palabras clave
trasplante de progenitores hematopoyéticos de sangre periférica, conservación de células madre a 4°C, criopreservación, mieloma múltiple
Cómo citar
Shanley, C., Bullorsky, E., Stemmelin, G., Berro, M., Kusminsky, G., Trucco, J., Milone, J., López, M., Martínez Rolón, J., Bentolila, G., Real, J., Milovic, V., Requejo, A., Dallasta, G., Gatto, S., & Jaimovich, G. (2019). Autotrasplante de progenitores hematopoyéticos de sangre periférica conservados a 4°C en mieloma múltiple. Comparación con métodos convencionales. Revista Hematología, 21(3), 263–273. Recuperado a partir de https://revistahematologia.com.ar/index.php/Revista/article/view/121
Resumen
El tratamiento de inducción seguido de consolidación con altas dosis de quimioterapia y posterior rescate con progenitores hematopoyéticos de sangre periférica autólogos (PHSP) es el tratamiento de elección en mieloma múltiple (MM) para pacientes aptos(1-6). Dado que el régimen condicionante que habitualmente se utiliza es melfalán (MEL) monodroga, que tiene una depuración rápida, hemos implementado una técnica simple y alternativa a la criopreservación celular con temperaturas ultra bajas (-80°C ó -196°C) conservando las células madre
a 4°C hasta su reinfusión sin el agregado de mezcla crioprotectante(7-9). En este contexto desarrollamos un estudio retrospectivo y multicéntrico comparando los resultados obtenidos por la técnica a 4°C con los del método convencional (-80°C/-196°C).
Citas
1. Gertz MA, Dingli D. How we manage autologous stem cell transplantation for multiple myeloma patients? Blood. 2014;124(6):882-90.
2. Cavo M, Rajkumar SV, Palumbo A, y col. International Myeloma Working Group consensus approach to the treatment of multiple myeloma
patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063-6073.
3. San Miguel JF, Mateos MV, Ocio E y col. Multiple myeloma: treatment evolution. Hematology. 2012;(Suppl 1): S3-S6.
4. Mohty M, Harousseau JL. Treatment of autologous stem cell eligible multiple myeloma patients: ten questions and answers. Haematologica. 2014;99(3):408-16.
5. Guías de Diagnóstico y Tratamiento. Edición 2015. Sociedad Argentina de Hematología.
6. Moreau P, Attal M, Facon T. Frontline therapy in multiple myeloma. Blood. 2015;125(20):3076-84.
7. Ruiz-Argüelles GJ, Ruiz Argüelles A, Pérez Romano B y col. Filgrastim-mobilized peripheral-blood stem cells can be stored at 4 degrees and used in autografts to rescue high-dose chemotherapy. Am J Hematol. 1995. Feb;48(2):100-103.
8. Lasky LC, McCullough J, Zanjani ED. Liquid storage of unseparated human bone marrow. Evaluation of hematopoietic progenitors by clonal assay. Transfusion. 1986; Jul-Aug;26(4):331-4.
9. Bullorsky E, Shanley C, Stemmelin G y col. Autotrasplante de stem cells hematopoyéticas criopreservadas a 4°C. Descripción de un método novedoso y sencillo para la consolidación
quimioterapeútica post-inducción en pacientes con mieloma múltiple. XXI Congreso Argentino de Hematología, I Simposio conjunto Asociación Hematológica Europea (EHA) y Sociedad
Argentina de Hematología (SAH). Hematología. 2013;17:154.
10. Gertz MA, Kumar SK, Lacy MQ y col. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple
myeloma. Bone Marrow Transplant. 2009;43(8): 619-625.
11. Winkler IG, Lévesque JP. Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. Exp Hematol. 2006;34:996-1009.
12. Moreau P, San Miguel J, Sonneveld P y col. Multiple Myeloma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow Up. Ann Oncol. 2017 Jul 1;28(suppl_4).
13. Raza S, Safyan RA, Rosenbaum E y col. Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Ther Adv Hematol. 2017 Feb;8(2):55-70.
14. Jethava YS, van Rhee F. Transplantation for Multiple Myeloma. Cancer Treat Res. 2016;169:227- 250.
15. Terpos E. International Myeloma Society. Multiple Myeloma: Clinical Updates from the American Society of Hematology Annual Meeting 2016. Clin Lymphoma Myeloma Leuk.
2017;17:329-339.
16. Skopec B, Skerget M, Zontar D y col. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients. Wien Klin Wochenschr. 2017 Apr24.
17. Stroncek DF, Fautsch SK, Lasky LC y col. Adverse reactions in patients transfused with cryopreserved marrow. Transfusion. 1991;31(6):521-6.
18. Zambelli A, Poggi G, Da Prada G y col. Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res. 1998; 18(6B):4705-8.
19. Windrum P, Morris TC, Drake MB y col. EBMT Chronic Leukaemia Working Party Complications Subcommittee. Variation in dimethyl sulfoxide use in stem cell transplantation: a survey
of EBMT centres. Bone Marrow Transpant. 2005 Oct;36(7):601.
20. Hoyt R, Szer J, Grigg A. Neurological events associated with the infusion of cryopreserved bone marrow and/or peripheral blood progenitor cells.
Bone Marrow Transplant. 2000 Jun;25(12):1285-7.
21. Otrock ZK, Beydoun A, Barada WM y col. Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells. Haematologica.
2008;93(3):e36-7.
22. Nath CE, Shaw PJ, Trotman J y col. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol. 2010 May;69(5):484-97.
23. Moreau P, Kerqueris MF, Milpied N y col. A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies:
pharmacokinetics and toxicity. Br J Hematol. 1996 Dec;95(3):527-30.
24. Donmez A, Cagirgan S, Saydam G y col. Overnight refrigerator storage of autologous peripheral progenitor stem cells without cryopreservation. Transfusion and Apheresis Science.
2007;36(3):313-319.
25. Pettengell R, Woll PJ, O’Connor DA y col. Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time.
Bone Marrow Transplant. 1994 Nov;14(5):703-9.
26. Cuellar-Ambrosi F, Karduss UA, Gomez wr y col. Hematologic reconstitution following highdose and supralethal chemoradiotherapy using stored, noncryopreserved autologous hematopoietic stem cells. Transplant Proc. 2004 JulAug;36(6):1704-5.
27. Seo JY, Huh HJ, Park HK y col. Evaluation of overnight storage conditions for autologous peripheral blood stem cell products: comparison of three different conditions. Vox Sang.
2012Aug;103(2):150-8.
28. Kao GS, Kim HT, Daley H y col. Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products. Transfusion. 2011 Jan;51(1):137-47.
29. Wannesson L, Panzarella T, Mikhael J y col. Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review. Annals of Oncology.
2007;18(4):623-632.
30. Kayal S, Sharma A, Igbal S y col. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical
Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells. Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):140-7.
31. Al-Anazi KA. Autologous Hematopoietic Stem
Cell Transplantation for Multiple Myeloma with-out Cryopreservation. Bone Marrow Res. 2012; 917361.
32. Ramzi M, Zakerinia M, Nourani H y col. Non-cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience. Clinical Transplantation.
2012;26(1):117-122.
33. Hechler G, Weide R, Heymanns J y col. Storage of noncryopreserved peripheral blood stem cells for transplantation. Annals of Hematology. 1996;72:303-306.
34. de Boer F, Drager AM, Pinedo HM y col. Extensive early apoptosis in frozen-thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral
blood progenitor cell transplantation. Bone Marrow Transplantation. 2002;29:249-255.
35. López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplantation.
2009;44(11):715-719.
2. Cavo M, Rajkumar SV, Palumbo A, y col. International Myeloma Working Group consensus approach to the treatment of multiple myeloma
patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063-6073.
3. San Miguel JF, Mateos MV, Ocio E y col. Multiple myeloma: treatment evolution. Hematology. 2012;(Suppl 1): S3-S6.
4. Mohty M, Harousseau JL. Treatment of autologous stem cell eligible multiple myeloma patients: ten questions and answers. Haematologica. 2014;99(3):408-16.
5. Guías de Diagnóstico y Tratamiento. Edición 2015. Sociedad Argentina de Hematología.
6. Moreau P, Attal M, Facon T. Frontline therapy in multiple myeloma. Blood. 2015;125(20):3076-84.
7. Ruiz-Argüelles GJ, Ruiz Argüelles A, Pérez Romano B y col. Filgrastim-mobilized peripheral-blood stem cells can be stored at 4 degrees and used in autografts to rescue high-dose chemotherapy. Am J Hematol. 1995. Feb;48(2):100-103.
8. Lasky LC, McCullough J, Zanjani ED. Liquid storage of unseparated human bone marrow. Evaluation of hematopoietic progenitors by clonal assay. Transfusion. 1986; Jul-Aug;26(4):331-4.
9. Bullorsky E, Shanley C, Stemmelin G y col. Autotrasplante de stem cells hematopoyéticas criopreservadas a 4°C. Descripción de un método novedoso y sencillo para la consolidación
quimioterapeútica post-inducción en pacientes con mieloma múltiple. XXI Congreso Argentino de Hematología, I Simposio conjunto Asociación Hematológica Europea (EHA) y Sociedad
Argentina de Hematología (SAH). Hematología. 2013;17:154.
10. Gertz MA, Kumar SK, Lacy MQ y col. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple
myeloma. Bone Marrow Transplant. 2009;43(8): 619-625.
11. Winkler IG, Lévesque JP. Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. Exp Hematol. 2006;34:996-1009.
12. Moreau P, San Miguel J, Sonneveld P y col. Multiple Myeloma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow Up. Ann Oncol. 2017 Jul 1;28(suppl_4).
13. Raza S, Safyan RA, Rosenbaum E y col. Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Ther Adv Hematol. 2017 Feb;8(2):55-70.
14. Jethava YS, van Rhee F. Transplantation for Multiple Myeloma. Cancer Treat Res. 2016;169:227- 250.
15. Terpos E. International Myeloma Society. Multiple Myeloma: Clinical Updates from the American Society of Hematology Annual Meeting 2016. Clin Lymphoma Myeloma Leuk.
2017;17:329-339.
16. Skopec B, Skerget M, Zontar D y col. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients. Wien Klin Wochenschr. 2017 Apr24.
17. Stroncek DF, Fautsch SK, Lasky LC y col. Adverse reactions in patients transfused with cryopreserved marrow. Transfusion. 1991;31(6):521-6.
18. Zambelli A, Poggi G, Da Prada G y col. Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res. 1998; 18(6B):4705-8.
19. Windrum P, Morris TC, Drake MB y col. EBMT Chronic Leukaemia Working Party Complications Subcommittee. Variation in dimethyl sulfoxide use in stem cell transplantation: a survey
of EBMT centres. Bone Marrow Transpant. 2005 Oct;36(7):601.
20. Hoyt R, Szer J, Grigg A. Neurological events associated with the infusion of cryopreserved bone marrow and/or peripheral blood progenitor cells.
Bone Marrow Transplant. 2000 Jun;25(12):1285-7.
21. Otrock ZK, Beydoun A, Barada WM y col. Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells. Haematologica.
2008;93(3):e36-7.
22. Nath CE, Shaw PJ, Trotman J y col. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol. 2010 May;69(5):484-97.
23. Moreau P, Kerqueris MF, Milpied N y col. A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies:
pharmacokinetics and toxicity. Br J Hematol. 1996 Dec;95(3):527-30.
24. Donmez A, Cagirgan S, Saydam G y col. Overnight refrigerator storage of autologous peripheral progenitor stem cells without cryopreservation. Transfusion and Apheresis Science.
2007;36(3):313-319.
25. Pettengell R, Woll PJ, O’Connor DA y col. Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time.
Bone Marrow Transplant. 1994 Nov;14(5):703-9.
26. Cuellar-Ambrosi F, Karduss UA, Gomez wr y col. Hematologic reconstitution following highdose and supralethal chemoradiotherapy using stored, noncryopreserved autologous hematopoietic stem cells. Transplant Proc. 2004 JulAug;36(6):1704-5.
27. Seo JY, Huh HJ, Park HK y col. Evaluation of overnight storage conditions for autologous peripheral blood stem cell products: comparison of three different conditions. Vox Sang.
2012Aug;103(2):150-8.
28. Kao GS, Kim HT, Daley H y col. Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products. Transfusion. 2011 Jan;51(1):137-47.
29. Wannesson L, Panzarella T, Mikhael J y col. Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review. Annals of Oncology.
2007;18(4):623-632.
30. Kayal S, Sharma A, Igbal S y col. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical
Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells. Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):140-7.
31. Al-Anazi KA. Autologous Hematopoietic Stem
Cell Transplantation for Multiple Myeloma with-out Cryopreservation. Bone Marrow Res. 2012; 917361.
32. Ramzi M, Zakerinia M, Nourani H y col. Non-cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience. Clinical Transplantation.
2012;26(1):117-122.
33. Hechler G, Weide R, Heymanns J y col. Storage of noncryopreserved peripheral blood stem cells for transplantation. Annals of Hematology. 1996;72:303-306.
34. de Boer F, Drager AM, Pinedo HM y col. Extensive early apoptosis in frozen-thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral
blood progenitor cell transplantation. Bone Marrow Transplantation. 2002;29:249-255.
35. López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplantation.
2009;44(11):715-719.
Todo el material publicado en la revista Hematología (versión electrónica y versión impresa), será cedido a la Sociedad Argentina de Hematología. De conformidad con la ley de derecho de autor (ley 11723) se les enviara a los autores de cada trabajo aceptado formulario de cesión de derechos de autor que deberá ser firmado por todos los autores antes de la publicación. Los autores deberán retener una copia del original pues la revista, no acepta responsabilidad por daños o pérdidas del material enviado. Los autores deberán remitir una versión electrónica al correo: revista@sah.org.ar
Descargas
Los datos de descargas todavía no están disponibles.